# Pembrolizumab (MK-3475) in MM Patients With Residual Disease

> **NCT02636010** · PHASE2 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 20 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02636010
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-07
- **Final completion:** 2020-02-20
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02636010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02636010, "Pembrolizumab (MK-3475) in MM Patients With Residual Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02636010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*